相关实验视频
Updated: Jan 9, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
针对急性免疫媒介性血栓性血栓细胞衰竭紫外线的量身定制治疗
Linus Alexander Völker1,2, Paul Thomas Brinkkötter1,2
1Department II, Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
早期诊断和新型抗·威尔布兰德因子 (VWF) 疗法正在改变免疫介导的血栓性血栓塞性紫外线 (iTTP) 治疗. 这些进步使人们能够转向无TPE协议,改善患者的治疗结果,并可能降低死亡率.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 罕见疾病 罕见疾病
背景情况:
- 免疫媒介性血栓性血栓性缺血性紫 (iTTP) 是一种关键的自身免疫性疾病.
- 它源于针对ADAMTS13的自身抗体,导致·维勒布兰德因子 (VWF) 失调.
- 目前的标准治疗包括治疗性血交换 (TPE),葡萄皮质类药物和免疫抑制剂.
研究的目的:
- 审查iTTP的新兴治疗策略.
- 强调早期诊断和干预的作用.
- 讨论无TPE治疗方案的可能性.
主要方法:
- 审查当前的文献和临床试验数据.
- 对新型抗VWF疗法的分析,如卡普拉西祖马布.
- 讨论诊断方法,包括ADAMTS13活动测试.
- 探索结合ADAMTS13水平和响应监测的治疗算法.
主要成果:
- 卡普拉西祖马布有效地阻止了血栓式微血管病变,并减少了复发.
- 早期诊断和干预促进了无TPE的治疗途径.
- ADAMTS13活动监测指导量身定制的治疗决策.
- 一种新的护理标准正在出现,它结合了抗VWF疗法,葡萄糖皮质类药物和早期免疫抑制.
结论:
- 新型疗法正在彻底改变iTTP管理.
- 及时诊断和及时治疗对于成功的结果至关重要.
- 显而易见的是,人们正在转向个性化,无TPE的治疗策略,这可能会降低死亡率.
更多相关视频
12:40Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
09:13Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
相关概念视频
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...